Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease

Clinical and Experimental Immunology

Volumn 173, Issue 1, 2013, Pages 102-111

  Liu, C ^a   Xia, X ^b   Wu, W ^a   Wu, R ^a   Tang, M ^a   Chen, T ^a   Xu, F ^b   Cong, Y ^c   Xu, X ^a   Liu, Z ^a  

^a TONGJI UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Crohn's disease; Infliximab; Interleukin 21; Mucosal healing; Th17 cells

Indexed keywords

C REACTIVE PROTEIN; CD3 ANTIBODY; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 21; MONOCLONAL ANTIBODY CD28; RETINOID RELATED ORPHAN RECEPTOR GAMMA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CROHN DISEASE; DOWN REGULATION; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOSTIMULATION; IN VITRO STUDY; INTESTINE MUCOSA; LAMINA PROPRIA; LYMPHOCYTIC INFILTRATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; TH17 CELL; ULCER HEALING;

ADULT; ANTIBODIES, MONOCLONAL; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CROHN DISEASE; DOWN-REGULATION; FEMALE; HUMANS; INTERLEUKIN-17; INTERLEUKINS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; REMISSION INDUCTION; TH17 CELLS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84878812016     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12084     Document Type: Article

References (37)

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361:2066-2078.
2. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448:427-434.
3. Di Sabatino A, Biancheri P, Rovedatti L etal. New pathogenic paradigms in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18:368-371.
4. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3:521-533.
5. Liu ZJ, Yadav PK, Su JL etal. Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol 2009; 15:5784-5788.
6. Maddur MS, Miossec P, Kaveri SV etal. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 2012; 181:8-18.
7. Ghoreschi K, Laurence A, Yang XP etal. T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol 2011; 32:395-401.
8. Van Limbergen J, Wilson DC, Satsangi J. The genetics of Crohn's disease. Annu Rev Genomics Hum Genet 2009; 10:89-116.
9. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 2008; 26:57-79.
10. Leonard WJ, Zeng R, Spolski R. Interleukin 21: a cytokine/cytokine receptor system that has come of age. J Leukoc Biol 2008; 84:348-356.
11. Monteleone G, Pallone F, MacDonald TT. Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses. Trends Immunol 2008; 29:290-294.
12. Monteleone G, Pallone F, MacDonald TT. Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease. Cytokine Growth Factor Rev 2009; 20:185-191.
13. Pallone F, Fina D, Caruso R etal. Role of IL-21 in inflammatory bowel disease. Exp Rev Clin Immunol 2010; 6:537-541.
14. MacDonald TT, Biancheri P, Sarra M etal. What's the next best cytokine target in IBD? Inflamm Bowel Dis 2012; 18:2180-2189.
15. Liu Z, Yang L, Cui Y etal. Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease. Inflamm Bowel Dis 2009; 15:1133-1134.
16. Danese S, Colombel JF, Reinisch W etal. Review article: infliximab for Crohn's disease treatment - shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 2011; 33:857-869.
17. ten Hove T, van Montfrans C, Peppelenbosch MP etal. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50:206-211.
18. Suenaert P, Bulteel V, Lemmens L etal. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 2002; 97:2000-2004.
19. Di Sabatino A, Pender SL, Jackson CL etal. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology 2007; 133:137-149.
20. Agnholt J, Kaltoft K. Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine 2001; 15:212-222.
21. Jürgens M, Mahachie John JM, Cleynen I etal. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011; 9:421-427.
22. Daperno M, D'Haens G, Van Assche G etal. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004; 60:505-512.
23. Liu Z, Yadav PK, Xu X etal. The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity. J Leukoc Biol 2011; 89:597-606.
24. Liu Z, Feng BS, Yang SB etal. Interleukin (IL)-23 suppresses IL-10 in the intestine of inflammatory bowel disease. J Biol Chem 2012; 287:3591-3597.
25. Liu Z, Chen X, Wang X etal. Chemokine CXCL11 links microbial stimuli to intestinal inflammation. Clin Exp Immunol 2011; 164:396-406.
26. Di Sabatino A, Ciccocioppo R, Cinque B etal. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004; 53:70-77.
27. Van den Brande JM, Braat H, van den Brink GR etal. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124:1774-1785.
28. Fina D, Sarra M, Fantini MC etal. Regulation of gut inflammation and Th17 cell response by interleukin-21. Gastroenterology 2008; 134:1038-1048.
29. Kageyama Y, Kobayashi H, Kato N. Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis. Mod Rheumatol 2009; 19:657-662.
30. Korn T, Bettelli E, Gao W etal. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007; 448:484-487.
31. Feng T, Qin H, Wang L etal. Th17 cells induce colitis and promote Th1 cell responses through IL-17 induction of innate IL-12 and IL-23 production. J Immunol 2011; 186:6313-6318.
32. + T helper cells. Cell 2006; 126:1121-1133.
33. Annunziato F, Cosmi L, Santarlasci V etal. Phenotypic and functional features of human Th17 cells. J Exp Med 2007; 204:1849-1861.
34. Elson CO, Cong Y, Weaver CT etal. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 2007; 132:2359-2370.
35. Jin Y, Lin Y, Lin L etal. IL-17/IFN-γ interactions regulate intestinal inflammation in TNBS-induced acute colitis. J Interferon Cytokine Res 2012; 32:548-556.
36. Kanayama K, Nakamura K, Ogino H etal. Th1 responses are more susceptible to infliximab-mediated immunosuppression than Th17 responses. Dig Dis Sci 2011; 56:3525-3533.
37. Shen H, Xia L, Lu J etal. Infliximab reduces the frequency of interleukin 17-producing cells and the amounts of interleukin 17 in patients with rheumatoid arthritis. J Investig Med 2010; 58:905-908.